Prima BioMed (NASDAQ:IMMP) Stock Rating Lowered by Wall Street Zen

Prima BioMed (NASDAQ:IMMP) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Prima BioMed in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Prima BioMed Stock Performance

Shares of Prima BioMed stock opened at $3.17 on Friday. The business has a fifty day simple moving average of $2.54 and a 200-day simple moving average of $2.04. Prima BioMed has a fifty-two week low of $1.32 and a fifty-two week high of $3.53.

Institutional Investors Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC increased its position in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.